Cover Image
市場調查報告書

Patrys Limited - 產品平台分析

Patrys Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 204924
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
Patrys Limited - 產品平台分析 Patrys Limited - Product Pipeline Review - 2015
出版日期: 2015年10月21日 內容資訊: 英文 45 Pages
簡介

Patrys Limited 是活用人類原本具有的天然抗體技術來治療癌症及其他許多疾病產品的製藥公司。

本報告提供Patrys Limited的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Patrys Limited的基本資料

Patrys Limited概要

  • 主要資訊
  • 企業資料

Patrys Limited:R&D概要

  • 主要的治療範圍

Patrys Limited:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Patrys Limited:開發中產品概況

Patrys Limited

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

Patrys Limited

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Patrys Limited:藥物簡介

  • PAT-SC1
  • PAT-SM6
  • PAT-CM1
  • PAT-LM1
  • PAT-NM1
  • PAT-NM2
  • PAT-NM3
  • PAT-SM3
  • PAT-SM5
  • Antibodies for Cancer
  • PAT-SM1
  • PAT-SM4

Patrys Limited:開發平台分析

Patrys Limited

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Patrys Limited:最近的開發平台趨勢

Patrys Limited:暫停中的計劃

Patrys Limited:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07670CDB

Summary

Global Markets Direct's, 'Patrys Limited - Product Pipeline Review - 2015', provides an overview of the Patrys Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Patrys Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Patrys Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Patrys Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Patrys Limited's pipeline products

Reasons to buy

  • Evaluate Patrys Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Patrys Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Patrys Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Patrys Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Patrys Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Patrys Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Patrys Limited Snapshot
    • Patrys Limited Overview
    • Key Information
    • Key Facts
  • Patrys Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Patrys Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Patrys Limited - Pipeline Products Glance
    • Patrys Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Patrys Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Patrys Limited - Drug Profiles
    • PATSM-6
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PAT-SC1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PAT-LM1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PATNM-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PATNM-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibodies for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PATH-12
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PATSM-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PATSM-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PATSM-4
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PATSM-5
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Patrys Limited - Pipeline Analysis
    • Patrys Limited - Pipeline Products by Target
    • Patrys Limited - Pipeline Products by Route of Administration
    • Patrys Limited - Pipeline Products by Molecule Type
    • Patrys Limited - Pipeline Products by Mechanism of Action
  • Patrys Limited - Recent Pipeline Updates
  • Patrys Limited - Dormant Projects
  • Patrys Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Patrys Limited, Key Information
  • Patrys Limited, Key Facts
  • Patrys Limited - Pipeline by Indication, 2015
  • Patrys Limited - Pipeline by Stage of Development, 2015
  • Patrys Limited - Monotherapy Products in Pipeline, 2015
  • Patrys Limited - Phase II, 2015
  • Patrys Limited - Phase I, 2015
  • Patrys Limited - Preclinical, 2015
  • Patrys Limited - Discovery, 2015
  • Patrys Limited - Pipeline by Target, 2015
  • Patrys Limited - Pipeline by Route of Administration, 2015
  • Patrys Limited - Pipeline by Molecule Type, 2015
  • Patrys Limited - Pipeline Products by Mechanism of Action, 2015
  • Patrys Limited - Recent Pipeline Updates, 2015
  • Patrys Limited - Dormant Developmental Projects,2015

List of Figures

  • Patrys Limited - Pipeline by Top 10 Indication, 2015
  • Patrys Limited - Pipeline by Stage of Development, 2015
  • Patrys Limited - Monotherapy Products in Pipeline, 2015
  • Patrys Limited - Pipeline by Top 10 Target, 2015
  • Patrys Limited - Pipeline by Top 10 Route of Administration, 2015
  • Patrys Limited - Pipeline by Top 10 Molecule Type, 2015
  • Patrys Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top